T1	Participants 50 83	cardiovascular events and cancer:
T2	Participants 213 246	cancer and cardiovascular events.
T3	Participants 448 502	cancer, cancer death, and major cardiovascular events.
T4	Participants 580 593	international
T5	Participants 723 890	patients at least 55 years old with vascular disease or diabetes mellitus was extended (HOPE-The Ongoing Outcomes [HOPE-TOO]) between April 16, 1999, and May 26, 2003.
T6	Participants 906 1003	267 HOPE centers that had enrolled 9541 patients, 174 centers participated in the HOPE-TOO trial.
T7	Participants 1007 1212	7030 patients enrolled at these centers, 916 were deceased at the beginning of the extension, 1382 refused participation, 3994 continued to take the study intervention, and 738 agreed to passive follow-up.
T8	Participants 2554 2605	patients with vascular disease or diabetes mellitus
